These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 25790292)

  • 21. Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors.
    Chlebowski RT; Col N
    Breast J; 2012; 18(4):299-302. PubMed ID: 22681627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. More treatment options for women with hormone receptor-positive breast cancer: guideline update, studies lead to advances in care.
    Printz C
    Cancer; 2014 Oct; 120(19):2939-40. PubMed ID: 25241884
    [No Abstract]   [Full Text] [Related]  

  • 23. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
    Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M
    Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Bria E; Carlini P; Cognetti F; Terzoli E; Giannarelli D
    J Natl Cancer Inst; 2007 Jan; 99(2):176; author reply 176-7. PubMed ID: 17228003
    [No Abstract]   [Full Text] [Related]  

  • 25. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
    Toi M; Saji S; Masuda N; Kuroi K; Sato N; Takei H; Yamamoto Y; Ohno S; Yamashita H; Hisamatsu K; Aogi K; Iwata H; Takada M; Ueno T; Saji S; Chanplakorn N; Suzuki T; Sasano H
    Cancer Sci; 2011 Apr; 102(4):858-65. PubMed ID: 21231986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence to adjuvant endocrine therapy in women with breast cancer.
    Danilak M; Chambers CR
    J Oncol Pharm Pract; 2013 Jun; 19(2):105-10. PubMed ID: 22895656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Chemoprevention of breast cancer: exemestane ready to be tested in study setting].
    Verkooijen HM; van Diest PJ; Peeters PH
    Ned Tijdschr Geneeskd; 2012; 156(1):A4217. PubMed ID: 22217312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update: a 62-year-old woman with a new diagnosis of breast cancer.
    Farag N; Burns R; Come SE
    JAMA; 2008 Mar; 299(9):1055-6. PubMed ID: 18319415
    [No Abstract]   [Full Text] [Related]  

  • 29. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aromatase inhibition: translation into a successful therapeutic approach.
    Geisler J; Lønning PE
    Clin Cancer Res; 2005 Apr; 11(8):2809-21. PubMed ID: 15837728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.
    Falandry C; Debled M; Bachelot T; Delozier T; Crétin J; Romestaing P; Mille D; You B; Mauriac L; Pujade-Lauraine E; Freyer G
    Breast Cancer Res Treat; 2009 Aug; 116(3):501-8. PubMed ID: 19020973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on the use of aromatase inhibitors in breast cancer.
    Brueggemeier RW
    Expert Opin Pharmacother; 2006 Oct; 7(14):1919-30. PubMed ID: 17020418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
    Mieog JS; Morden JP; Bliss JM; Coombes RC; van de Velde CJ;
    Lancet Oncol; 2012 Apr; 13(4):420-32. PubMed ID: 22265698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exemestane: an alternative treatment option in early breast cancer. Foreward.
    Jassem J;
    Anticancer Drugs; 2008 Feb; 19 Suppl 1():S1. PubMed ID: 18340241
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.
    Saladores PH; Precht JC; Schroth W; Brauch H; Schwab M
    Expert Rev Mol Diagn; 2013 May; 13(4):349-65. PubMed ID: 23638818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
    Ingle JN
    Steroids; 2011 Jul; 76(8):765-7. PubMed ID: 21382394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
    Gibson K; O'Bryant CL
    J Oncol Pharm Pract; 2008 Sep; 14(3):139-45. PubMed ID: 18719068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure.
    Prescrire Int; 2001 Aug; 10(54):108-9. PubMed ID: 11718178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of patients with metastatic breast cancer.
    Cruz Jurado J; Richart Aznar P; García Mata J; Fernández Martínez R; Peláez Fernández I; Sampedro Gimeno T; Galve Calvo E; Murillo Jaso L; Polo Marqués E; García Palomo A
    Adv Ther; 2011 Sep; 28 Suppl 6():50-65. PubMed ID: 21922395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Examination of the use of Exemestane in patients with metastatic breast cancer.
    Takashima S; Kiyoto S; Takahashi M; Hara F; Takabatake D; Aogi K; Ohsumi S
    Breast Cancer; 2011 Jul; 18(3):189-94. PubMed ID: 21437667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.